The 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) is at the half-way point in Chicago, IL. With PD-1 checkpoint inhibitors maturing at a breakneck pace, much attention at the meeting has already turned to PD-1 combination therapies. These combinations include the much-anticipated IDO inhibitor, epacadostat (INCY), featured across six abstracts, and CAR-T therapies.

Other major data in the first three days of the meeting included the success of the LATITUDE trial of Zytiga (abiraterone, JNJ) in metastatic hormone-naïve prostate cancer, potentially greatly expanding the target patient population for the drug. Also featured were positive data from the OlympiAD trial of Lynparza (olaparib, AZN) which could become the first PARP inhibitor approved in breast cancer. New targets are always of interest, and we have highlighted abstracts from the LAG-3 inhibitor, BMS-986016 (BMY) and the anti-GITR compound, BMS-986156 (BMY).

This mid-meeting report is a compilation of our coverage through the first three days of the 2017 ASCO meeting and includes a list of the weekend data events we have added into Biomedtracker to date along with commentary on key presentations by our analysts attending the meeting. Additional coverage through the rest of the meeting will be added to the database over the next few days and compiled in our post-meeting report.


For our disclosures, please read the Biomedtracker Research Standards.